Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector

Abstract

Recent data suggest that many tumors, such as malignant gliomas, have disrupted pRB function, either because of RB-1 gene mutations or as a result of mutations affecting upstream regulators of pRB such as cyclin D1 or p16/INK4a/MTS1 (ref. 1–5). Tumor suppression by pRB has been linked to its ability to repress E2F-responsive promoters such as the E2F-1 promoter6,7. Thus, a prediction, which has not yet been demonstrated experimentally in vivo, is that E2F-responsive promoters should be more active in tumor cells relative to normal cells because of an excess of “free” E2F and loss of pRB/E2F represser complexes. We demonstrate that adenoviral vectors that contain transgenes driven by the E2F-1 promoter can mediate tumor-selective gene expression in vivo, allowing for eradication of established gliomas with significantly less normal tissue toxicity than seen with standard adenoviral vectors. Our data indicate that de-repression of the E2F-1 promoter occurs in cancer cells in vivo, a finding that can be exploited to design viral vectors that mediate tumor-selective gene expression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 81, 323–330 (1995).

    Article  CAS  Google Scholar 

  2. He, J. et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54, 5804–5807 (1994).

    CAS  Google Scholar 

  3. Ueki, K. et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56, 150–153 (1996).

    CAS  PubMed  Google Scholar 

  4. Jen, J. et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353–6358 (1994).

    CAS  Google Scholar 

  5. Schmidt, E.E., Ichimura, K., Reifenberger, G. & Collins, V.P. CDKN2/p16/MTSI/ gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54, 6321–6324 (1994).

    CAS  Google Scholar 

  6. Adams, P.D. & Kaelin, W.G. Transcriptional control by E2F. Semin. Cancer Biol. 6, 99–108 (1995).

    Article  CAS  Google Scholar 

  7. Sellers, W.R., Neuman, E. & Kaelin, W.G. The retinoblastoma protein contains a potent transrepression domain which induces a cell-cycle block when bound to DNA. Proc. Natl. Acad. Sci. USA 92, 11544–11548 (1995).

    Article  CAS  Google Scholar 

  8. Tevosian, S.G., Paulson, K.E., Branson, R. & Yee, A.S. Expression of the E2F-1/DP-1 transcription factor in murine development. Cell Growth Differ. 7, 43–52 (1996).

    CAS  PubMed  Google Scholar 

  9. Kaelin, W.G. et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70, 351–364 (1992).

    Article  CAS  Google Scholar 

  10. Neuman, E., Flemington, E.K., Sellers, W.R. & Kaelin, W.G. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 14, 6607–6615 (1994).

    Article  CAS  Google Scholar 

  11. Johnson, D.G., Kiyoshi, O. & Nevins, J.R. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514–1525 (1994).

    Article  CAS  Google Scholar 

  12. Hsiao, K.-M., McMahon, S.L. & Farnham, P. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev. 8, 1526–1537 (1994).

    Article  CAS  Google Scholar 

  13. Johnson, D.G. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene 11, 1685–1692 (1995).

    CAS  PubMed  Google Scholar 

  14. McGrory, W.J., Bautista, D.S. & Graham, F.L. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163, 614–617 (1988).

    Article  CAS  Google Scholar 

  15. Ghosh-Choudhury, G., Haj-Ahmad, Y., Brinkley, P., Rudy, J. & Graham, F.L. Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 50, 161–171 (1986).

    Article  CAS  Google Scholar 

  16. Culver, K.W. et al. In vivo gene transfer with retroviral-vector producer cells for treatment of experimental brain tumors. Science 256, 1550–1552 (1992).

    Article  CAS  Google Scholar 

  17. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. & Oldfield, E.H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 3475–3485 (1993).

    Google Scholar 

  18. Fine, H.A. Prospects for gene therapy as an innovative approach to malignant gliomas. Perspect. Neural. Surg. 5, 115–127 (1994).

    Google Scholar 

  19. Manome, Y. et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside In vitro and in vivo. Nature Med. 2, 567–573 (1996).

    Article  CAS  Google Scholar 

  20. Goodman, J. et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir; pathologic, radiographic, and molecular studies. Hum. Gene Ther. 7, 1241–50 (1996).

    Article  CAS  Google Scholar 

  21. Fults, D., Brockmeyer, D., Tullous, M.W., Pedone, C.A. & Cawthone, R.M. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res. 52, 674–679 (1992).

    CAS  PubMed  Google Scholar 

  22. Dong, Y. et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum. Gene Ther. 7, 713–720 (1996).

    Article  CAS  Google Scholar 

  23. Graham, F.L., Smiley, J., Russel, W.C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–72 (1977).

    Article  CAS  Google Scholar 

  24. Kobayashi, N., Allen, N., Clendenon, N.R. & Ko, L.-W. An improved rat brain-tumor model. J. Neurosurg. 53, 808–815 (1980).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parr, M., Manome, Y., Tanaka, T. et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3, 1145–1149 (1997). https://doi.org/10.1038/nm1097-1145

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1097-1145

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing